Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade)

Integra LifeSciences ( IART ) has had a miserable time of it since the mid-2023 announcement of quality control issues at the company’s Boston plant that not only sapped important growth drivers in the Tissue Technologies business but also necessitatedAnalyst’s Disclosure: I/we have a beneficial long position in the shares of SOLV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than fr ...